Eli Lilly’s weight-loss drug Mounjaro comes to India, eyes big market with increasing obesity and diabetes risk
Trending News
1 week, 1 day ago

Eli Lilly’s weight-loss drug Mounjaro comes to India, eyes big market with increasing obesity and diabetes risk

Live Mint  

Eli Lilly launched its blockbuster diabetes and weight-loss drug Mounjaro in India on Thursday, March 20, beating rival Novo Nordisk for a much-awaited entry into the world's most populous country grappling with high rates of obesity and diabetes. According to global media reports, US-based Lilly and Danish Novo Nordisk have seen skyrocketing global demand for their innovative weight-loss drugs, with investor interest also boosting the drugmakers' valuations. "The dual burden of obesity and type 2 diabetes is rapidly emerging as a major public health challenge in India," said President and General Manager Winselow Tucker at Lilly India. Wegovy and Novo's diabetes drug, Ozempic — which has the same main ingredient — and Mounjaro, belong to a class of therapies known as GLP-1 receptor agonists that help control blood sugar and slow digestion, making people feel fuller for longer.

India Diabetes Obesity Cent Reuters Novo Mounjaro Lilly Drug Wegovy  india  cent  market  mounjaro  lillys  drug  wegovy  weightloss  mg  obesity  risk  eyes  lilly  increasing  diabetes  global  eli

History of this topic

Mounjaro arrives in India: Game-changer or not?
Trending News
2 days, 4 hours ago

Mounjaro arrives in India: Game-changer or not?

Hindustan Times  

The Ozempic craze is not yet over. “Mounjaro’s ability to regulate appetite, improve insulin sensitivity, and reduce liver sugar production sets it apart from other diabetes medications,” informs Dr Sharwari Dabhade, endocrinologist at Madhukar Rainbow Children’s Hospital. "Studies show that Mounjaro can support weight loss even in people without diabetes. “Regular monitoring of a patient is important while on this …

'Ozempic-like' weight loss drug Mounjaro creates buzz amid India launch: Price per month, availability, pros and cons
2 days, 6 hours ago

'Ozempic-like' weight loss drug Mounjaro creates buzz amid India launch: Price per month, availability, pros and cons

Hindustan Times  

Amy Schumer has praised weight loss drug Mounjaro after a not-so-great experience with Wegovy years prior. Originally developed for type 2 diabetes, it has shown remarkable weight loss benefits — helping overweight individuals without diabetes lose up to 20–25 percent of their body weight, while those with diabetes experience around 15 percent reduction,” Dr Rajiv Kovil says. Dr Aparna Govil …

Weight-loss drug Mounjaro in India: Is it better than Ozempic?
1 week ago

Weight-loss drug Mounjaro in India: Is it better than Ozempic?

Firstpost  

US pharmaceutical company Eli Lilly has launched Mounjaro, a diabetes and weight-loss drug, in India. As new drugs to treat diabetes and prompt weight loss gain popularity worldwide, US-based pharmaceutical company Eli Lilly has launched its ‘game-changing’ medication in India. Drugs such as Mounjaro and Ozempic help regulate blood sugar levels in people with type 2 diabetes by mimicking these …

Milind Deora slams weight-loss drug Mounjaro's launch, calls for higher sugar taxes
1 week ago

Milind Deora slams weight-loss drug Mounjaro's launch, calls for higher sugar taxes

India Today  

The recent launch of Mounjaro, a widely popular drug for weight-loss and type 2 diabetes, in India has sparked criticism from Rajya Sabha member Milind Deora, who questioned the growing influence of Western pharmaceutical solutions on India's health landscape. While the drug's introduction in India reflects the rising demand for weight management solutions amid increasing obesity and diabetes rates, Deora's …

Mounjaro enters India as weight-loss drug, but doctors warn against misuse
1 week ago

Mounjaro enters India as weight-loss drug, but doctors warn against misuse

India Today  

The much-awaited anti-diabetes and weight-loss drug Mounjaro, developed by US pharmaceutical giant Eli Lilly, was launched in India on March 20. Dr. Ashutosh Goyal, Senior Consultant Endocrinologist at Paras Health Gurugram, called Mounjaro’s availability in India a “big step forward” in diabetes and obesity management. "By combining pharmaceuticals with personalised care, we can help improve patient outcomes and mitigate the …

Eli Lilly launches its blockbuster weight loss drug Mounjaro in India
1 week ago

Eli Lilly launches its blockbuster weight loss drug Mounjaro in India

Live Mint  

Mumbai: US drugmaker Eli Lilly & Co. brought its anti-obesity drug Mounjaro to India on Thursday, marking the country's first treatment of its kind, with monthly costs ranging from ₹14,000 to ₹17,500. Weight loss drugs such as Mounjaro help the body manage blood sugar more effectively, make one feel less hungry, and slow digestion, so the person feels full longer. …

Mounjaro Enters India: The Weight Loss & Diabetes Drug May Have These Side Effects; Know Price
1 week ago

Mounjaro Enters India: The Weight Loss & Diabetes Drug May Have These Side Effects; Know Price

ABP News  

Eli Lilly and Company has launched Mounjaro, a once-a-week injectable prescription medication, following approval from the Central Drugs Standard Control Organization. Mounjaro represents an important step in metabolic health management,” said Dr. Manish Mistry, Senior Medical Director, Eli Lilly India. Potential Link to Rare Eye Disease According to a report in Reuters, Danish health authorities in December 2024 requested a …

Blockbuster weight-loss drug Mounjaro comes to India: How does it work?
1 week, 1 day ago

Blockbuster weight-loss drug Mounjaro comes to India: How does it work?

Firstpost  

The popular anti-obesity drug Mounjaro has finally been launched in India. The development comes after Eli Lilly received approval from India’s Central Drugs Standard Control Organisation. Eli Lilly has received approval from India’s Central Drugs Standard Control Organisation to launch Mounjaro. ‘First of its kind’ “It is a first-of-its-kind treatment for obesity, overweight, and type 2 diabetes that activates both …

Obesity and diabetes management drug launched in India by American pharma company Eli Lilly
Trending News
1 week, 1 day ago

Obesity and diabetes management drug launched in India by American pharma company Eli Lilly

The Hindu  

American pharmaceutical major Eli Lilly and Company on Thursday launched its diabetes and obesity management drug Mounjaro in India. Novo Nordisk’s oral semaglutide tablet, Rybelsus, launched in India in January 2022, has already captured nearly 65% of the anti-obesity drug market along with other weight loss medications, including dulaglutide, orlistat, and liraglutide. Obesity, a chronic relapsing disease and a major …

Mounjaro: Eli Lilly launches popular weight-loss drug in India
Top News
1 week, 1 day ago

Mounjaro: Eli Lilly launches popular weight-loss drug in India

Hindustan Times  

Eli Lilly and Company on Thursday announced the launch of its globally popular weight-loss injectable drug, Mounjaro, in India. Mounjaro is also indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus,” read the company statement. Chemically known as Tirzepatide, the drug was evaluated in two robust global clinical development programs: …

Mounjaro, popular weight-loss drug, launched in India. Here's how much it costs
1 week, 1 day ago

Mounjaro, popular weight-loss drug, launched in India. Here's how much it costs

India Today  

Popular anti-diabetes and obesity drug Mounjaro has been launched in India, by the US-based pharmaceutical giant Eli Lilly, after receiving marketing authorisation from India's drug regulator - the Central Drugs Standard Control Organisation. The prescription drug is recommended for: Adults with obesity Adults who are overweight and have other health problems related to weight Adults with type 2 diabetes to …

Why don't celebrities admit to taking weight-loss medicine? Expert answers at India Today Conclave
3 weeks ago

Why don't celebrities admit to taking weight-loss medicine? Expert answers at India Today Conclave

India Today  

Many celebrities who have undergone dramatic transformations have avoided admitting to using weight loss drugs, despite its growing popularity. Addressing this reluctance, Vikrant Shrotriya, Corporate Vice President & Managing Director of Novo Nordisk India, said, "They just want to pat their back that they have fantastic genes. Watch the full India Today Conclave 2025 here During a session on obesity …

Ozempic maker Novo Nordisk prepared to enter India despite patent expiry, generic competition
3 weeks, 1 day ago

Ozempic maker Novo Nordisk prepared to enter India despite patent expiry, generic competition

Live Mint  

Danish drugmaker Novo Nordisk is prepared to enter the Indian market and other markets with its blockbuster drug Ozempic, despite losing patent exclusivity early next year. “Even as we face patent expiration for Semaglutide, we’ll probably still launch the product in markets and volume growth, and to do that we need to have a very large manufacturing footprint,” Lars Fruergaard …

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
1 month, 3 weeks ago

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

Associated Press  

Eli Lilly’s profit doubled in the fourth quarter, propelled by its hot-selling diabetes and obesity treatments, and the drugmaker came out with a mostly better-than-expected 2025 forecast. Sales of Lilly’s top-selling product, the diabetes treatment Mounjaro, jumped 60% to $3.53 billion in the final quarter of 2024 while its obesity treatment counterpart Zepbound brought in $1.9 billion. Analysts expect more …

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024
1 month, 3 weeks ago

Diabetes and obesity drugs fuel Eli Lilly profit in the final quarter of 2024

The Independent  

For free real time breaking news alerts sent straight to your inbox sign up to our breaking news emails Sign up to our free breaking news emails Sign up to our free breaking news emails SIGN UP I would like to be emailed about offers, events and updates from The Independent. Read our privacy policy Eli Lilly’s profit doubled in …

Eli Lilly likely to launch weight loss & anti-diabetes drug in India: Is it safe to consume?
1 month, 3 weeks ago

Eli Lilly likely to launch weight loss & anti-diabetes drug in India: Is it safe to consume?

Live Mint  

US-based pharmaceutical company Eli Lilly is planning to launch Mounjaro, an anti-diabetes and weight loss drug in India by 2025 after regulatory approvals, reported News18 citing officials from the company. We haven’t yet finalised the pricing strategy for the Tirzapedite, but our pricing will reflect the medicine’s efficacy and the fact that it improves overall health and reduces the economic …

Elli Lilly’s weight loss drug to be covered in Medicare insurance in US for THIS treatment - all you need to know
2 months, 2 weeks ago

Elli Lilly’s weight loss drug to be covered in Medicare insurance in US for THIS treatment - all you need to know

Live Mint  

Eli Lilly's obesity drug Zepbound can now be covered by government-backed Medicare insurance plans for use in sleep apnea, broadening access to the blockbuster weight-loss treatment. The Wednesday statement from the Centers for Medicare & Medicaid Services comes after Zepbound in December became the first drug approved in the U.S. for sleep apnea, strengthening its case for coverage as Medicare …

Why the Obesity Drug Revolution Is a Work in Progress
2 months, 3 weeks ago

Why the Obesity Drug Revolution Is a Work in Progress

Bloomberg  

A new class of weight-loss drugs known as GLP-1s are proving to be game changers for people with obesity. They’re also minting billions for pharmaceutical companies, especially the companies that developed them, Eli Lilly & Co. and Novo Nordisk A/S. It also remains unclear whether pharma companies can actually deliver on the promise of even better weight-loss drugs — part …

It’s getting harder to claim success with weight reduction drugs
2 months, 3 weeks ago

It’s getting harder to claim success with weight reduction drugs

Live Mint  

In a new study, an experimental obesity drug from Novo Nordisk, CagriSema allowed people to lose more than 20% of their body weight, on average, a result that caused the Danish company’s stock price to fall by as much as 29%. CagriSema is a combination of the GLP-1 agonist semaglutide, the ingredient found in Novo’s Ozempic and Wegovy, and cagrilintide, …

MATT RIDLEY: Move over, Ozempic: Why an astonishing new class of weight-loss drugs will soon end obesity FOR EVER - and here are the other surprising illnesses they could treat
2 months, 3 weeks ago

MATT RIDLEY: Move over, Ozempic: Why an astonishing new class of weight-loss drugs will soon end obesity FOR EVER - and here are the other surprising illnesses they could treat

Daily Mail  

Imagine if you could eat your fill on Christmas Day then dial down your appetite for January. The past year has seen the rise of myriad weight-loss drugs that are getting better and achieving results where decades of hectoring and dieting have failed – in yet another miracle of biomedical science. Yes cancer, dementia and anxiety are on the rampage; …

Eli Lilly new trial is all about the battle to be best weight-loss drug zepbound and wegovy
3 months, 3 weeks ago

Eli Lilly new trial is all about the battle to be best weight-loss drug zepbound and wegovy

India Today  

In a study trial, pharmaceutical giant Eli Lilly's weight-loss drug Zepbound showed better results than another pharmaceutical company, Novo Nordisk's weight-loss drug Wegovy. The trial, called SURMOUNT-5, compared Zepbound to Wegovy, which is a mono GLP-1 receptor agonist in adults living with obesity without diabetes. The results showed Zepbound delivering a remarkable 47% greater relative weight loss compared to Wegovy, …

Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says
3 months, 3 weeks ago

Weight-loss meds go head-to-head in new study. One was significantly more effective, drugmaker says

The Independent  

Sign up to our free Living Well email for advice on living a happier, healthier and longer life Live your life healthier and happier with our free weekly Living Well newsletter Live your life healthier and happier with our free weekly Living Well newsletter SIGN UP I would like to be emailed about offers, events and updates from The Independent. …

Eli Lilly’s Zepbound beats Novo Nordisk’s Wegovy in first head-to-head study
3 months, 3 weeks ago

Eli Lilly’s Zepbound beats Novo Nordisk’s Wegovy in first head-to-head study

Live Mint  

In the first head-to-head test, Eli Lilly’s Zepbound obesity drug helped people lose significantly more weight than its main competitor, Novo Nordisk’s Wegovy. The details People taking Zepbound lost 20.2% of their body weight on average after 72 weeks of treatment in the Lilly- That translated into an average 50-pound loss for people who took Zepbound, while Wegovy users lost …

Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms
3 months, 3 weeks ago

Novo Nordisk India execs urge early Wegovy launch as weight-loss rival looms

Live Mint  

* Novo Nordisk India team fears losing competitive edge to Eli Lilly * Novo's Wegovy and Lilly's Mounjaro are GLP-1 receptor agonists * India's obesity rates rising, increasing demand for weight-loss drugs By Leroy Leo and Rishika Sadam BENGALURU/HYDERABAD, Dec 3 - Novo Nordisk's team in India has been pushing the Danish drugmaker's global leadership for an earlier launch of …

Novo Nordisk’s Wegovy launches in China, offering obesity drug at a fraction of US prices
4 months, 1 week ago

Novo Nordisk’s Wegovy launches in China, offering obesity drug at a fraction of US prices

Salon  

Semaglutide and tirzepatide medications have transformed weight loss, diabetes management, and overall health in recent years. According to Reuters and CNN, Novo Nordisk announced Monday that it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market, where more than 180 million people live with obesity. Eli Lilly, Novo Nordisk’s direct competitor and the manufacturer of …

Medicaid fuels US coverage of Novo, Lilly weight-loss drugs
4 months, 1 week ago

Medicaid fuels US coverage of Novo, Lilly weight-loss drugs

Live Mint  

* U.S. government health plans cover 52.2 million for new weight-loss drugs * An estimated 24.4 million in commercial plans have similar coverage * Fourteen state Medicaid programs cover GLP-1 drugs for obesity By Chad Terhune Nov 18 - U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the reimbursement available …

Weight-loss drug Wegovy launched in China
4 months, 1 week ago

Weight-loss drug Wegovy launched in China

CNN  

Novo Nordisk said Monday it has launched its popular obesity drug Wegovy in China, the world’s second-largest pharmaceuticals market where it estimates more than 180 million people live with obesity. Novo gained approval for Wegovy in China in June and will initially target Chinese patients willing to pay out-of-pocket for the weekly injectable drug. Strong sales there and in the …

Big Pharma’s obesity bonanza faces new tests
4 months, 3 weeks ago

Big Pharma’s obesity bonanza faces new tests

Live Mint  

In terms of recent stock-market frenzies, the Ozempic trade nearly tops the list, second only to speculation that artificial intelligence will soon be writing this column. Powerful weight-loss drugs like Wegovy and Zepbound have driven nearly $1 trillion in market-capitalization gains, with most of those gains flowing to Eli Lilly and Novo Nordisk, the dominant players in the obesity-drug market. …

Eli Lilly is gaining on Novo Nordisk in the obesity race
7 months, 2 weeks ago

Eli Lilly is gaining on Novo Nordisk in the obesity race

Live Mint  

The two companies’ divergent earnings reports this week showed that Indianapolis-based Lilly is moving faster than its Denmark-headquartered counterpart in the race to win the GLP-1 war. Less than a year after approval, Eli Lilly’s weekly prescription volume of Zepbound is about where Novo was with Wegovy volume more than two years in, according to JPMorgan data. And while all …

Rivals emerge to Ozempic and Zepbound—but with a lag
8 months, 1 week ago

Rivals emerge to Ozempic and Zepbound—but with a lag

Live Mint  

The two dominant players in the obesity market will eventually make way for a few more competitors. On Wednesday, Roche’s stock gained 5.6%, adding roughly $14 billion to its market value, after it reported that Carmot’s once-daily pill helped patients lose 7.3% of their body weight at the four-week mark. While the data was from an early-stage study, it was …

Wegovy weight-loss drug OK'd in China
9 months ago

Wegovy weight-loss drug OK'd in China

China Daily  

By AI HEPING in New York | chinadaily.com.cn | Updated: 2024-06-26 14:54 FILE PHOTO: A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Danish drugmaker Novo Nordisk said Tuesday that its injectable weight-loss drug Wegovy has been approved in China, where the proportion of overweight and …

Wegovy weight-loss drug OK'd in China
9 months ago

Wegovy weight-loss drug OK'd in China

China Daily  

FILE PHOTO: A view shows the logo of Novo Nordisk at the company's office in Bagsvaerd, on the outskirts of Copenhagen, Denmark, March 8, 2024. Danish drugmaker Novo Nordisk said Tuesday that its injectable weight-loss drug Wegovy has been approved in China, where the proportion of overweight and obese adults reached almost 51 percent of the country's 1.4 billion people …

Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, Mounjaro
10 months ago

Eli Lilly beefs up plan to expand manufacturing for popular drugs Zepbound, Mounjaro

Associated Press  

Eli Lilly will spend more than $5 billion to expand an Indiana manufacturing site and eventually make more doses of its popular weight-loss and diabetes treatments, Zepbound and Mounjaro. The company broke ground for its Lebanon, Indiana, manufacturing plant last year and expects to start making products there near the end of 2026. But Lilly has struggled to make enough …

Wegovy: At least 25,000 people in the US are starting weight-loss drug each week, drugmaker says
10 months, 3 weeks ago

Wegovy: At least 25,000 people in the US are starting weight-loss drug each week, drugmaker says

CNN  

CNN — Drugmaker Novo Nordisk said it’s been increasing supply of its sought-after weight-loss drug Wegovy, with at least 25,000 people now starting to take the medicine each week in the United States. We’re talking about, many patients, chronic treatment.” Eli Lilly, Novo Nordisk’s biggest competitor, also said this week it expects supply to increase later this year. “While we …

Eli Lilly Obesity Drug In India Likely Next Year: Report
1 year, 1 month ago

Eli Lilly Obesity Drug In India Likely Next Year: Report

ABP News  

Eli Lilly, the renowned US drugmaker, is gearing up to introduce its widely acclaimed diabetes medication, Mounjaro, along with its successful obesity treatment, to the Indian market as early as next year. With soaring obesity rates, particularly among women, and the second-highest number of individuals with type-2 diabetes globally, India presents an enticing opportunity for pharmaceutical companies. According to Reuters, …

Weight loss, diabetes drugs propel Eli Lilly to better-than-expected forecast for 2024
1 year, 1 month ago

Weight loss, diabetes drugs propel Eli Lilly to better-than-expected forecast for 2024

The Independent  

Sign up to our free Living Well email for advice on living a happier, healthier and longer life Live your life healthier and happier with our free weekly Living Well newsletter Live your life healthier and happier with our free weekly Living Well newsletter SIGN UP I would like to be emailed about offers, events and updates from The Independent. …

Weight loss, diabetes drugs propel Eli Lilly to largely better-than-expected forecast for 2024
1 year, 1 month ago

Weight loss, diabetes drugs propel Eli Lilly to largely better-than-expected forecast for 2024

Associated Press  

Eli Lilly rode soaring demand for diabetes and weight-loss treatments to a better-than-expected finish in 2023, and the drugmaker expects momentum to carry into the new year. Lilly said on Tuesday that revenue could climb as much as 22% this year, as star sellers like the diabetes drug Mounjaro and its new weight-loss counterpart, Zepbound, gain market share. Zepbound, a …

Novo Nordisk pays $25.8 million to promote its obesity drug
1 year, 3 months ago

Novo Nordisk pays $25.8 million to promote its obesity drug

Live Mint  

During his address, Dr. Lee Kaplan urged fellow doctors to use their prescription pads to fight the obesity crisis, according to a report by Reuters on December 1. Dr. Kaplan, a leading U.S. weight-loss specialist, recommended turning to new weight-loss medicines like Novo Nordisk's Wegovy to reduce obesity. “We are going to have to use these medications,” he said at …

Diabetes drug Mounjaro already in short supply months after launching in Australia
1 year, 3 months ago

Diabetes drug Mounjaro already in short supply months after launching in Australia

ABC  

A new diabetes medication being prescribed off-label for weight loss is already experiencing shortages, just weeks after becoming available in Australia. Key points: Despite only being released into the Australian market a few months ago, Mounjaro is in short supply It has been approved by the TGA as a diabetes treatment but is being prescribed "off-label" for weight loss The …

Big Pharma scrambles to feed demand for weight-loss treatments amid rising US obesity rates
1 year, 4 months ago

Big Pharma scrambles to feed demand for weight-loss treatments amid rising US obesity rates

Associated Press  

NEW YORK — Obesity rates in the U.S. have been rising steadily for well over a decade and some of the world’s biggest drug developers are tapping into the growing treatment market. It notably priced the drug at roughly a 20% discount to Novo Nordisk’s Wegovy as the companies try to entice more employers to include weight-loss drugs in their …

Lilly weight-loss drug Zepbound gets US, UK approval to rival Wegovy
1 year, 4 months ago

Lilly weight-loss drug Zepbound gets US, UK approval to rival Wegovy

Hindustan Times  

U.S. and UK regulators both gave the thumbs up to Eli Lilly's weight-loss treatment called Zepbound on Wednesday, paving the way for a powerful new rival to Novo Nordisk's Wegovy in addressing record obesity rates. U.S. and UK regulators approved the Lilly drug for use by adults with a body mass index - a measure of weight based on height …

A new version of the diabetes drug Mounjaro can be used for weight loss, FDA says
1 year, 4 months ago

A new version of the diabetes drug Mounjaro can be used for weight loss, FDA says

Associated Press  

A new version of the popular diabetes treatment Mounjaro can be sold as a weight-loss drug, U.S. regulators announced Wednesday. Zepbound is the latest diabetes drug approved for chronic weight management, joining Novo Nordisk’s Wegovy, a high-dose version of its diabetes treatment Ozempic. “This would be the most highly efficacious drug ever approved for the treatment of obesity,” said Dr. …

FDA approves new version of diabetes drug Mounjaro for weight loss
1 year, 4 months ago

FDA approves new version of diabetes drug Mounjaro for weight loss

LA Times  

Zepbound, a new version of the popular diabetes treatment Mounjaro, received government approval Wednesday to be sold as a weight-loss drug. Zepbound is the latest diabetes drug approved for weight loss, joining Novo Nordisk’s Wegovy, a high-dose version of its diabetes treatment Ozempic. “This would be the most highly efficacious drug ever approved for the treatment of obesity,” said Dr. …

Ozempic-maker Novo Nordisk becomes biggest company in Europe amid worldwide scramble for 'miracle' weight-loss drug
1 year, 6 months ago

Ozempic-maker Novo Nordisk becomes biggest company in Europe amid worldwide scramble for 'miracle' weight-loss drug

ABC  

What do you think the biggest company in Denmark is? Novo Nordisk's humble beginnings Danish company Novo Nordisk has made diabetes medicine for 100 years. How Hollywood's Ozempic drug use went mainstream Photo shows An unidentified woman in gold shoes and a long lace train walking up stairs In the past year, Ozempic has become increasingly popular with celebrities, tech …

Soaring sales of diabetes drug Mounjaro, widely used for weight loss, sends Eli Lilly to new heights
1 year, 7 months ago

Soaring sales of diabetes drug Mounjaro, widely used for weight loss, sends Eli Lilly to new heights

Associated Press  

INDIANAPOLIS — Eli Lilly’s diabetes treatment Mounjaro, which is widely used for weight loss, raked in nearly $1 billion in second-quarter sales, or more than $200 million above what Wall Street had expected. Shares of the drugmaker soared 17% to an all-time-high Tuesday after Lilly said Mounjaro sales swelled more than 70% since the first quarter to $980 million. If …

Eli Lilly releases more data for new obesity drug, moving toward fast-track approval
1 year, 11 months ago

Eli Lilly releases more data for new obesity drug, moving toward fast-track approval

NPR  

Eli Lilly releases more data for new obesity drug, moving toward fast-track approval Enlarge this image toggle caption Eli Lilly & co. Eli Lilly & co. Now, the company is seeking approval from the Food and Drug Administration for tirzepatide for chronic weight management in people who have obesity or are overweight with weight-related conditions, but don't have diabetes. Sponsor …

What to know about prescription drugs promising weight loss
2 years ago

What to know about prescription drugs promising weight loss

Associated Press  

WeightWatchers, the 60-year-old diet firm, announced this week it would acquire a telehealth company whose providers prescribe anti-obesity drugs for growing numbers of eager online subscribers. The $132 million deal with Sequence is the just the latest commercial push into the red-hot market for prescription drugs that promise significant weight loss. In a clinical trial, adults who took Wegovy saw …

The ‘next Ozempic’ became a social media sensation. Then everything changed
2 years ago

The ‘next Ozempic’ became a social media sensation. Then everything changed

The Independent  

Sign up to our free Living Well email for advice on living a happier, healthier and longer life Live your life healthier and happier with our free weekly Living Well newsletter Live your life healthier and happier with our free weekly Living Well newsletter SIGN UP I would like to be emailed about offers, events and updates from The Independent. …

A diabetes drug for weight loss? It’s going to cost you
3 years, 7 months ago

A diabetes drug for weight loss? It’s going to cost you

LA Times  

The logo of Danish pharmaceutical giant Novo Nordisk is pictured atcompany headquarters in Bagsvaerd, outside of Copenhagen, Denmark. It’s too early to know yet how many employers will cover Wegovy, although about 40% currently offer a similarly priced, but less effective, weight-loss injectable drug also made by Novo Nordisk. Wegovy’s effectiveness may also put pressure on the Medicare program, which …

Discover Related